Nortiva Bio launches with $5M Gates Foundation grant for once-monthly oral contraceptive
What's the deal? Nortiva BioDealroom has a profile for this one. Try Dealroom → has launched as a clinical-stage biopharmaceutical company developing a once-monthly oral contraceptive, backed by a $5M grant from the Gates Foundation. The Lexington, Massachusetts-based company is a wholly owned subsidiary of InnovivaDealroom has a profile for this one. Try Dealroom → (Nasdaq: INVA), which acquired the underlying LYNX drug delivery platform from Lyndra Therapeutics in 2025.
The LYNX platform uses a standard-size capsule containing a structure that unfolds in the stomach, where it stays for up to a month, releasing drug at a controlled rate. The technology is protected by more than 50 granted patents and originated in the MIT laboratories of Robert Langer and Giovanni Traverso, who co-founded Lyndra Therapeutics.
Langer — an MIT Institute Professor and co-founder of more than 40 biotech companies including ModernaDealroom has a profile for this one. Try Dealroom → — serves as advisory board chair.
Why now? Nortiva cited data showing roughly 50% of women miss at least one oral contraceptive dose per month. A once-monthly formulation could address this compliance gap, particularly in low-resource settings where access to injectable or implantable alternatives is limited.
The Gates Foundation grant frames the contraceptive programme as both a mission-driven initiative and a platform validation exercise. The programme remains at preclinical stage for the LYNX-specific formulation.
What could go wrong? The platform completed a Phase III study under Lyndra, but the contraceptive formulation itself is still preclinical — meaning years of clinical development lie ahead. No external venture financing was disclosed, making the company reliant on Innoviva's balance sheet and grants to fund its pipeline.
Beyond the lead programme, Nortiva is pitching the LYNX platform as a partnering vehicle for pharma companies to reformulate small-molecule drugs into monthly oral regimens. No specific partnership agreements have been announced.
The signal: The Gates Foundation's $5M grant to an early stage corporate subsidiary — rather than a standalone startup — underscores a growing willingness among global health funders to back commercially structured vehicles when the underlying science aligns with access goals. It also highlights long-acting drug delivery as a category attracting philanthropic capital alongside traditional venture funding, particularly where daily dosing remains a barrier to real-world efficacy.
Read more: AllSci
